Kuhn KS et al
In 2020, medical studies highlighted that GLP-1 agonists like Ozempic could exacerbate symptoms of diabetic gastroparesis in patients with pre-existing conditions
One incident involving a ventilator malfunction near an MRI became known to Zoll on June 20, 2024, but FDA received the MDR, 1220908202500947, for the corresponding incident on March 10, 2025, which is beyond the 30calendar day timeframe
Genetic variations in these processes can pinpoint a subset of women and men with increased lifetime exposure to estrogens, estrogen metabolites, and other carcinogens
"Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor"
Figure 1: Social Mentions of Obesity By Platform (December 2024 November 2025) Roughly 11 percent of these mentions focused directly on antiobesity medicines, with half of those centred on two brands: Wegovy and Mounjaro